Elsevier | GenomeWeb

Elsevier

Down to the Deadline

ScienceInsider says a consortium of German institutions and the publisher Elsevier are still working out a deal for journal access.

The integrated products will provide a seamless workflow for interpreting next-generation sequence data from alignment through pathway analysis.

The company is working on a bespoke pharmacovigilance product that will leverage its biomedical content, and has added an NGS module to Pathway Studio. 

Under the terms of the agreement, the companies will combine software products and data to improve NGS analysis and interpretation

This week, GenomeQuest launched a new Intellectual Property Management module for its software that lets customers manage their sequence IP.

NEW YORK (GenomeWeb) – Elsevier, a provider of scientific, technical, and medical information products and services, said this week that it has linked two of its databases to provide pharmaceutical companies with better risk monitoring and improved pharmacovigilance resources.

Elsevier has released a new version of its Reaxys workflow solution which offers an improved user interface with new search functionality that makes running queries easier.

Gene Codes has released Sequencher 5.2, the latest version of its DNA sequence data analysis software.

Because most pure-play bioinformatics companies aren't publicly traded, the sector doesn’t have the financial barometer that things like quarterly earnings reports provide, making it somewhat challenging to gauge growth and speculate about future gains.

Elsevier said this week that Karo Bio has licensed its Reaxys suite to help its chemists identify and prioritize viable drug compounds for further research and development.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.